(Q77569207)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9819101%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

review article

1 reference

title

Atherothrombogenicity of lipoprotein(a): the debate (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9819101%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

author name string

A M Scanu

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9819101%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

publication date

1 November 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9819101%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Cardiology

6 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9819101%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

volume

82

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9819101%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

issue

9A

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9819101%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

page(s)

26Q-33Q

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9819101%20AND%20SRC:MED&resulttype=core&format=json

A NEW SERUM TYPE SYSTEM IN MAN—THE Lp SYSTEM

6 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Structural basis for the presumptive atherothrombogenic action of lipoprotein(a). Facts and speculations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Lipoprotein (a). Heterogeneity and biological relevance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

cDNA sequence of human apolipoprotein(a) is homologous to plasminogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Lipoprotein(a): Nonhuman primate models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Sequence polymorphisms in the apo(a) gene associated with specific levels of Lp(a) in plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

A pentanucleotide repeat polymorphism in the 5' control region of the apolipoprotein(a) gene is associated with lipoprotein(a) plasma concentrations in Caucasians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Significant impact of the +93 C/T polymorphism in the apolipoprotein(a) gene on Lp(a) concentrations in Africans but not in Caucasians: confounding effect of linkage disequilibrium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

C/T polymorphism in the 5' untranslated region of the apolipoprotein(a) gene introduces an upstream ATG and reduces in vitro translation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Comparative analysis of the apo(a) gene, apo(a) glycoprotein, and plasma concentrations of Lp(a) in three ethnic groups. Evidence for no common "null" allele at the apo(a) locus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Reduction of lecithin-cholesterol acyltransferase, apolipoprotein D and the Lp(a) lipoprotein with the anabolic steroid stanozolol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Hormonal regulation of serum Lp (a) levels. Opposite effects after estrogen treatment and orchidectomy in males with prostatic carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

The lowering of lipoprotein[a] induced by estrogen plus progesterone replacement therapy in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Effect of postmenopausal estrogen replacement on plasma Lp(a) lipoprotein concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Increased concentrations of serum lipoprotein (a) in response to growth hormone treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Hormonal regulation of serum lipoprotein(a) levels. Contrasting effects of growth hormone and insulin-like growth factor-I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Lipoprotein(a) in patients treated by continuous ambulatory peritoneal dialysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Prealbumin and lipoprotein(a) in hemodialysis: relationships with patient and vascular access survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Lipoprotein(a) and treatment of chronic renal disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Serum lipoprotein (a) levels in maintenance hemodialysis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Lipoprotein (a) levels in end-stage renal failure and renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Transient changes of serum lipoprotein(a) as an acute phase protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Lp(a): an acute-phase reactant?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Elevated levels of lipoprotein(a) in women with preeclampsia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Plasma concentrations of Lp(a) lipoprotein and TGF-beta1 are altered in preeclampsia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Modification of serum apolipoprotein A-I, apolipoprotein B and lipoprotein(a) levels after bisphosphonates-induced acute phase response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

The refined structure of the epsilon-aminocaproic acid complex of human plasminogen kringle 4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Rhesus monkey lipoprotein(a) binds to lysine Sepharose and U937 monocytoid cells less efficiently than human lipoprotein(a). Evidence for the dominant role of kringle 4(37).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

A single point mutation (Trp72-->Arg) in human apo(a) kringle 4-37 associated with a lysine binding defect in Lp(a)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Lys and fibrinogen binding of wild-type (Trp72) and mutant (Arg72) human apo(a) kringle IV-10 expressed in E coli and CHO cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Determinants of lipoprotein(a) assembly: a study of wild-type and mutant apolipoprotein(a) phenotypes isolated from human and rhesus monkey lipoprotein(a) under mild reductive conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Identification of two functionally distinct lysine-binding sites in kringle 37 and in kringles 32-36 of human apolipoprotein(a).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Polymorphonuclear cells isolated from human peripheral blood cleave lipoprotein(a) and apolipoprotein(a) at multiple interkringle sites via the enzyme elastase. Generation of mini-Lp(a) particles and apo(a) fragments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Oxidative modification of lipoprotein(a) and the effect of beta-carotene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Apolipoprotein(a) kringle 4-containing fragments in human urine. Relationship to plasma levels of lipoprotein(a).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Localization of nonpancreatic secretory phospholipase A2 in normal and atherosclerotic arteries. Activity of the isolated enzyme on low-density lipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Lipoprotein(a) interactions with lipid and nonlipid risk factors in early familial coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Proliferation of human smooth muscle cells promoted by lipoprotein(a)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Apolipoprotein(a) binds via its C-terminal domain to the protein core of the proteoglycan decorin. Implications for the retention of lipoprotein(a) in atherosclerotic lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Apolipoprotein(a) is a human vascular endothelial cell agonist: studies on the induction in endothelial cells of monocyte chemotactic factor activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Lipoprotein(a) enhances the expression of intercellular adhesion molecule-1 in cultured human umbilical vein endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Lp(a) lipoprotein is a major risk factor for cardiovascular disease: pathogenic mechanisms and clinical significance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Oxidation of lipoprotein Lp(a). A comparison with low-density lipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Oleate stimulates the formation of triglyceride-rich particles containing apoB100-apo(a) in long-term primary cultures of human hepatocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Homocysteine and atherothrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Aspirin improves endothelial dysfunction in atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Lipoprotein (a) displays increased accumulation compared with low-density lipoprotein in the murine arterial wall

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

Lipoprotein(a) levels in the nephrotic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

7 January 2021

Lipoprotein(a), fibrin binding, and plasminogen activation.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

7 January 2021

Lipoprotein (a) and coronary heart disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

7 January 2021

Therapy for lowering lipoprotein (a) levels

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900733-4

7 January 2021

10.1016/S0002-9149(98)00733-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9819101%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1 reference